Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Blood (2021) 138 (Supplement 1): 80.

https://doi.org/10.1182/blood-2021-152112

Published: 2021

Journal Articles

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

Blood (2021) 138 (Supplement 1): 82.

https://doi.org/10.1182/blood-2021-147897

Published: 2021

Journal Articles

Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion

Blood (2021) 138 (Supplement 1): 728.

https://doi.org/10.1182/blood-2021-150913

Published: 2021

Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Blood (2019) 134 (Supplement_1): 695.

https://doi.org/10.1182/blood-2019-121694

Published: 2019

Journal Articles

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Christie P.M. Verkleij, MD, Monique C. Minnema, Okke de Weerdt, MD, Patricia W.C. Bosman, MSc, Kristine A. Frerichs, MD, Alexandra J. Croockewit, MD PhD, Saskia K. Klein, MD PhD, Gerard Bos, MD PhD, Tuna Mutis, Wouter J. Plattel, MD, Ellen van der Spek, MD PhD, Annemiek Broyl, MD PhD, Pieter Sonneveld, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Niels W. C. J. Van De Donk, MD PhD

Blood (2019) 134 (Supplement_1): 1879.

https://doi.org/10.1182/blood-2019-124339

Published: 2019

Journal Articles

Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study

Kristine A. Frerichs, MD, Monique C. Minnema, Mark-David Levin, MD PhD, Annemiek Broyl, MD PhD, Gerard Bos, MD PhD, Marie José Kersten, MD PhD, Tuna Mutis, Christie P.M. Verkleij, MD, Patricia W.C. Bosman, MSc, Saskia K. Klein, MD PhD, Sonja Zweegman, MD PhD, Pieter Sonneveld, Niels W. C. J. Van De Donk, MD PhD

Blood (2019) 134 (Supplement_1): 1826.

https://doi.org/10.1182/blood-2019-123383

Published: 2019

Journal Articles

Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial

Blood (2018) 132 (Supplement 1): 800.

https://doi.org/10.1182/blood-2018-99-111650

Published: 2018

Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, PhD, Mark-David Levin, MDPhD, Noortje Thielen, MD PhD, Saskia K. Klein, MD PhD, Inge Ludwig, MD MSc, Matthijs Westerman, MD, Paula F Ypma, MDPhD, Yavuz Bilgin, MDPhD, Maaike Sohne, MD, Esther de Waal, PhD, Niels WCJ van de Donk, MD PhD, Pieter Sonneveld, MDPhD, Sonja Zweegman, MDPhD

Blood (2018) 132 (Supplement 1): 596.

https://doi.org/10.1182/blood-2018-99-114668

Published: 2018

Journal Articles

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, PhD, Mark-David Levin, MDPhD, Saskia K. Klein, MD PhD, Esther de Waal, PhD, Corien Eeltink, Charlotte L.B.M. Korst, MD, Paula F Ypma, MDPhD, Amanda C. Dijk, MD, Matthijs Westerman, MD, Wendy Deenik, MD, Bea Tanis, PhD, Monique C Minnema, MD PhD, Henk M.W. Verheul, MD PhD, Birgit I. Lissenberg-Witte, PhD, Niels WCJ van de Donk, MD PhD, Pieter Sonneveld, MD PhD, Sonja Zweegman, MD PhD

Blood (2018) 132 (Supplement 1): 1889.

https://doi.org/10.1182/blood-2018-99-116920

Published: 2018

Journal Articles

Feasibility and Efficacy of Dose Adjusted Melphalan - Prednisone - Bortezomib (MPV) in Elderly Patients ≥ 75 Years of Age with Newly Diagnosed Multiple Myeloma; the Non-Randomised Phase II HOVON 123 Study

Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Saskia K. Klein, MD PhD, Esther G.M. De Waal, MD, Corien M. Eeltink, RN, MA, ANP, Paula F. Ypma, MD, Amanda C. Dijk, MD, Matthijs Westerman, MD, Wendy Deenik, MD PhD, Bea Tanis, MD PhD, Monique S. Slee-Valentijn, MD, Monique Minnema, Heleen Visser-Wisselaar, PhD, Claudia Stege, MD, Niels W.C.J. van de Donk, MD PhD, Kazem Nasserinejad, MA, Pieter Sonneveld, MD PhD

Blood (2016) 128 (22): 3305.

https://doi.org/10.1182/blood.V128.22.3305.3305

Published: 2016

Journal Articles

Lenalidomide with or without Erythropoietin and Granulocyte-Colony Stimulating Factor Shows Efficacy in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndrome with or without Del 5q, Refractory or Unlikely to Respond to Erythropoietin. Results of a HOVON89 Phase II Randomized Multicenter Study. (EudraCT 2008-002195-10)

Blood (2016) 128 (22): 224.

https://doi.org/10.1182/blood.V128.22.224.224

Published: 2016

Journal Articles

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Blood (2016) 128 (19): 2297–2306.

https://doi.org/10.1182/blood-2016-07-729236

Published: 2016

Includes: Supplemental data

Journal Articles

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

Blood (2016) 127 (9): 1109–1116.

https://doi.org/10.1182/blood-2015-11-679415

Published: 2016

Includes: Supplemental data

Journal Articles

Modulation of CD38 Expression Levels on Multiple Myeloma Tumor Cells By All- Trans Retinoic Acid Improves the Efficacy of the Anti-CD38 Monoclonal Antibody Daratumumab

Inger S. Nijhof, MD, Henk M. Lokhorst, MDPhD, Berris van Kessel, Richard W.J. Groen, PhD, Anton C. Martens, PhD, Parul Doshi, PhD, Saskia K. Klein, MDPhD, Tuna Mutis, MDPhD, Kate Sasser, Niels W.C.J. van de Donk, MDPhD

Blood (2014) 124 (21): 2096.

https://doi.org/10.1182/blood.V124.21.2096.2096

Published: 2014

Journal Articles

Randomized Phase III Trial in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma Comparing Melphalan-Prednisone-Thalidomide Followed By Thalidomide Maintenance (MPT-T) Versus Melphalan-Prednisone-Lenalidomide Followed By Maintenance with Lenalidomide (MPR-R); A Joint Study of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and the Nordic Myeloma Study Group (NMSG)

Blood (2014) 124 (21): 179.

https://doi.org/10.1182/blood.V124.21.179.179

Published: 2014

Journal Articles

Erythroid Lineage Analysis By Flow Cytometry Is of Highly Additive Value for MDS Diagnosis: A Study on Behalf of the HOVON89 Study Group

Eline MP Cremers, MD, Theresia M Westers, PhD, Canan Alhan, MD, Claudia Cali, Heleen A Visser-Wisselaar, PhD, Dana A Chitu, PhD, Marian JPL Stevens-Kroef, PhD, Pedro Silva Coelho, MD, Edo Vellenga, MDPhD, Saskia K. Klein, MDPhD, Pierre W. Wijermans, MDPhD, Georgine E De Greef, Marie-Cecile Legdeur, MD PhD, Petra Muus, MD PhD, Gert J Ossenkoppele, MD PhD, Joop H Jansen, PhD, Arjan A Van de Loosdrecht, MD PhD

Blood (2014) 124 (21): 4667.

https://doi.org/10.1182/blood.V124.21.4667.4667

Published: 2014

Journal Articles

Validation Of a Multi-Diagnostic Approach Including Flow Cytometry To Identify Specific Risk Categories Within Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group

Eline M.P. Cremers, MD, Theresia M. Westers, PhD, Canan Alhan, MD, Claudia Cali, Heleen A. Visser-Wisselaar, PhD, Dana A Chitu, PhD, Marian J.P.L. Stevens-Kroef, PhD, Pedro Silva Coelho, MD, Edo Vellenga, MD, PhD, Saskia K. Klein, MD PhD, Pierre W. Wijermans, MD, PhD, Georgine E. de Greef, MD, PhD, Martijn R. Schaafsma, MD, PhD, M Marwijk Kooy, MD, PhD, Petra Muus, MD, PhD, Gert J. Ossenkoppele, MD PhD, Joop H. Jansen, PhD, Arjan A. van de Loosdrecht, MD, PhD

Blood (2013) 122 (21): 1521.

https://doi.org/10.1182/blood.V122.21.1521.1521

Published: 2013

Journal Articles

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Inger S. Nijhof, MD, Sonja Zweegman, MD PhD, Mark-David Levin, MD PhD, Harry R. Koene, MD PhD, Aart Beeker, MD, Andries C. Bloem, PhD, Gerard M.J. Bos, MD PhD, Laura M. Faber, MD PhD, Saskia K. Klein, MD PhD, Evert-Jan F.M. de Kruijf, MD, Ellen van der Spek, MD PhD, Shulamiet Wittebol, MD PhD, Jeroen F. van Velzen, Berris van Kessel, Tuna Mutis, MD, PhD, Pieter Sonneveld, MD, Ph.D, Henk Lokhorst, Niels W.C.J. van de Donk, MD, PhD

Blood (2013) 122 (21): 287.

https://doi.org/10.1182/blood.V122.21.287.287

Published: 2013

Journal Articles

Escalated Dose Bortezomib Once Weekly Combined with Lenalidomide and Dexamethasone (eVRD) Followed by Lenalidomide Maintenance in First Relapse of Multiple Myeloma (MM). the HOVON 86 Phase 2 Trial

Pieter Sonneveld, MD, Okke de Weerdt, Mark-David Levin, Wendimagegn Ghidey, Edo Vellenga, Saskia K Klein, Jeanette Doorduyn, Marie José Kersten, P.W. Wijermans, MD, PhD, Henk Lokhorst, MD

Blood (2012) 120 (21): 1853.

https://doi.org/10.1182/blood.V120.21.1853.1853

Published: 2012

Journal Articles

Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,

Blood (2011) 118 (21): 3989.

https://doi.org/10.1182/blood.V118.21.3989.3989

Published: 2011

NARROW

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study

Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Feasibility and Efficacy of Dose Adjusted Melphalan - Prednisone - Bortezomib (MPV) in Elderly Patients ≥ 75 Years of Age with Newly Diagnosed Multiple Myeloma; the Non-Randomised Phase II HOVON 123 Study

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

Modulation of CD38 Expression Levels on Multiple Myeloma Tumor Cells By All- Trans Retinoic Acid Improves the Efficacy of the Anti-CD38 Monoclonal Antibody Daratumumab

Erythroid Lineage Analysis By Flow Cytometry Is of Highly Additive Value for MDS Diagnosis: A Study on Behalf of the HOVON89 Study Group

Validation Of a Multi-Diagnostic Approach Including Flow Cytometry To Identify Specific Risk Categories Within Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group

Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study)

Escalated Dose Bortezomib Once Weekly Combined with Lenalidomide and Dexamethasone (eVRD) Followed by Lenalidomide Maintenance in First Relapse of Multiple Myeloma (MM). the HOVON 86 Phase 2 Trial

Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only